F. Morschhauser

2.0k citations

27 papers · 944 indexed · h-index 13

Impact in

Pathology and Forensic Medicine top 2%
- Lymphoma Diagnosis and Treatment
Genetics top 5%
- Chronic Lymphocytic Leukemia Research

Papers in

Pathology and Forensic Medicine 22
- Lymphoma Diagnosis and Treatment 22
Genetics 8
- Chronic Lymphocytic Leukemia Research 8

Co-authors: Olivier Casasnovas Pierre Feugier Réda Bouabdallah Pierre Fenaux Claude Preudhomme Daniel Olive Luc Xerri Jean Michel Picquenot
Journals: Blood (6 papers)Journal of Clinical Oncology (4 papers)Haematologica (4 papers)Hematological Oncology (4 papers)European Journal of Nuclear Medicine and Molecular Imaging (2 papers)
Partner nations: France United States Belgium

In The Last Decade

F. Morschhauser

27 papers receiving 935 citations

Peers

Countries citing papers authored by F. Morschhauser

Since Specialization

Citations

This map shows the geographic impact of F. Morschhauser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. Morschhauser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. Morschhauser more than expected).

Fields of papers citing papers by F. Morschhauser

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F. Morschhauser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. Morschhauser. The network helps show where F. Morschhauser may publish in the future.

Co-authors

The 25 scholars most cited alongside F. Morschhauser, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with F. Morschhauser Line = papers co-authored together F. Morschhauser links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	280 \| GLOFITAMAB COMBINED WITH R‐CHOP OR POLA‐R‐CHP IN PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B‐CELL LYMPHOMA: FINAL RESULTS FROM THE NP40126 STUDY Hematological Oncology ·Max S. Topp, Monica Tani, Michael Dickinson, Nilanjan Ghosh, Armando Santoro, Lima Neto, Francesc Bosch, Christopher P. Fox, Armando López Guillermo, Thomas Gastinne, Andreas Viardot, William Townsend, Wei-Li Shih, H. Tilly, Muhammad Fahim, Florence Perret, S Kirk, Chin‐Lee Wu, Martin Barrett, F. Morschhauser	2025	1
2	A new pharmacokinetic model for 90Y-ibritumomab tiuxetan based on 3-dimensional dosimetry Scientific Reports ·F. Morschhauser, Rüdiger Ballhorn, C. Baillet, Christine Barthélémy, 潘学峰, J. Fulcrand, Pierre Bigot, D. Huglo, Bertrand Décaudin, Nicolas Simon, X. B. Xu	2018	2
3	FDG-PET–driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study Blood ·Olivier Casasnovas, Loïc Ysebaert, Catherine Thiéblemont, Emmanuel Bachy, Patrick Feugier, Alain Delmer, Sabine Tricot, Jean Gabarre, Marc André, Christophe Fruchart, Nicolas Mounier, Richard Delarue, Michel Meignan, Alina Berriolo-Riedinger, Stéphane Bardet, J Emile, Jean-Philippe Jaı̈s, Corinne Haïoun, Hervé Tilly, F. Morschhauser	2017	62
4	Eight Cycles of ABVD Versus Four Cycles of BEACOPP_escalatedPlus Four Cycles of BEACOPP_baselinein Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial Journal of Clinical Oncology ·Patrice Carde, Matthias Karrasch, Catherine Fortpied, Pauline Brice, Hussein Khaled, Olivier Casasnovas, Denis Caillot, Isabelle Gaillard, Serge Bologna, Christophe Fermé, Pieternella J. Lugtenburg, F. Morschhauser, Igor Aurer, Bertrand Coiffier, Ralph M. Meyer, Matthew D. Seftel, Max Wolf, Bengt Glimelius, Anna Sureda, Nicolas Mounier	2016	75
5	IMPACT OF PRIOR TREATMENT ON PFS FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA PATIENTS RANDOMIZED TO LENALIDOMIDE VS INVESTIGATOR'S CHOICE: A SUBGROUP ANALYSIS OF THE PHASE II MCL-002 (SPRINT) STUDY Haematologica ·Marek Trněný, Lai Thai Dao, Jan Walewski, David Belada, Jiří Mayer, John Radford, Wojciech Jurczak, F. Morschhauser, Zaky Pratiwi, Simon Rule, Tsvetan Biyukov, Meera Patturajan, Shirley Berman, Luca Arcaini	2015	2
6	Identification of MUM1 as a prognostic immunohistochemical marker in follicular lymphoma using computerized image analysis Human Pathology ·Luc Xerri, Emmanuel Bachy, Bettina Fabiani, Danielle Canioni, Catherine Chassagne‐Clément, Shir Ying Chai, Frédéric Charlotte, Nicole Brousse, Marie‐Christine Rousselet, Charles Foussard, Pauline Brice, Pierre Feugier, F. Morschhauser, Anne Sonet, Daniel Olive, Gilles Salles	2014	21
7	Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma Haematologica ·Emmanuel Bachy, Roch Houot, F. Morschhauser, Anne Sonet, Pauline Brice, Karim Belhadj, Guillaume Cartron, B. Audhuy, Christophe Fermé, Pierre Feugier, Catherine Sebban, Vincent Delwail, Hervé Maisonneuve, Steven Le Gouill, Sophie Lefort, Nicole Brousse, C. Foussard, Gilles Salles, (unknown)	2013	60
8	Comparisons of dosimetric approaches for fractionated radioimmunotherapy of non-Hodgkin lymphoma. PubMed ·Ludovic Ferrer, 潘学峰, Caroline Bodet‐Milin, Steven Le Gouill, Leni Lutfiani, 闻正, 高明來, Jill Tipping, D. Huglo, Philippe Carpentier, Tim Illidge, Françoise Kraeber‐Bodéré, F. Morschhauser, Manuel Bardiès	2012	8
9	Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B) Annals of Oncology ·Nicolas Ketterer, Karsten Kemper, Catherine Thiéblemont, Christophe Fermé, J Brière, Olivier Casasnovas, Serge Bologna, B. Christian, Thierry Connerotte, Christian Récher, Dominique Bordessoule, Christophe Fruchart, Richard Delarue, Christophe Bonnet, F. Morschhauser, Bruno Anglaret, Carole Soussain, Bettina Fabiani, H. Tilly, Corinne Haïoun	2012	21
10	Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA Haematologica ·Marie‐Hélène Delfau‐Larue, Laurence de Leval, Bertrand Joly, Anne Plonquet, Dominique Challine, Marie Parrens, Alain Delmer, Gilles Salles, F. Morschhauser, Richard Delarue, P. Rat, Réda Bouabdallah, Olivier Casasnovas, Hervé Tilly, Philippe Gaulard, Corinne Haïoun	2012	61
11	Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA Haematologica ·Olivier Fitoussi, Karim Belhadj, Nicolas Mounier, Marie Parrens, H. Tilly, Gilles Salles, Pierre Feugier, I. Ben-Zvi, Loïc Ysebaert, Jean Gabarre, Raoul Herbrecht, Maud Janvier, Éric Van Den Neste, F. Morschhauser, Olivier Casasnovas, Hervé Ghesquières, Bruno Anglaret, Sabine Bréchignac, Corinne Haïoun, Christian Gisselbrecht	2011	54
12	Comparison of dosimetric approaches for Non-Hodgkin lymphoma in radioimmunotherapy European Journal of Nuclear Medicine and Molecular Imaging ·Ludovic Ferrer, 潘学峰, Caroline Bodet‐Milin, Steven Le Gouill, Leni Lutfiani, 闻正, 高明來, Jill Tipping, Tim Illidge, Françoise Kraeber‐Bodéré, F. Morschhauser, Manuel Bardiès	2010	1
13	Dosimetry for fractionated ZevalinTM treatment as an initial therapy of follicular lymphoma. European Journal of Nuclear Medicine and Molecular Imaging ·潘学峰, Ludovic Ferrer, Manuel Bardiès, Caroline Bodet‐Milin, Françoise Kraeber‐Bodéré, D. Huglo, Steven Le Gouill, Leni Lutfiani, 闻正, Jill Tipping, 高明來, Tim Illidge, F. Morschhauser	2010	1
14	Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21) Leukemia ·Harmony Leroy, Stéphane de Botton, Nathalie Grardel, Stéphane Darre, Xavier Leleu, Christophe Roumier, F. Morschhauser, J L Laï, F Bauters, Pierre Fenaux, Claude Preudhomme	2005	97
15	Assessing the Predictive Value of Plasma FLT3-L Levels for Hematologic Toxicity after Yttrium-90 Ibritumomab Tiuxetan ([90Y]-Zevalin) Given as Consolidation in Patients with Advanced B-Cell Follicular NHL Responding to First Line Therapy. Blood ·F. Morschhauser, John Radford, Ambro van Hoof, Claire Barraud, A. Chlistalla, Anton Hagenbeek	2005	2
16	First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin’s lymphoma (HL) Journal of Clinical Oncology ·Evert M. Noordijk, José Thomas, Royan Richard, Nanji Yang, Pauline Brice, Marine Diviné, F. Morschhauser, Patrice Carde, Houchingue Eghbali, M. Henry‐Amar	2005	76
17	Four ABVD and Involved-Field Radiotherapy in Unfavorable Supradiaphragmatic Clinical Stages (CS) I-II Hodgkin’s Lymphoma (HL): Preliminary Results of the EORTC-GELA H9-U Trial. Blood ·Christophe Fermé, Marine Diviné, Andrej Vranovský, F. Morschhauser, Réda Bouabdallah, Jean Gabarre, Judith A. Cheek, Richard Delarue, Vittorina Zagonel, J. Jaubert, Anton Hagenbeek, Zhuwei Li, Chantal Rieux, José Thomas, M. Henry‐Amar	2005	24
18	Prognostic factors for aggressive lymphoma patients treated with front-line autotransplantation after complete remission: A cohort study on 330 patients Blood ·Nicolas Mounier, Christian Gisselbrecht, Josette Brière, Corinne Haïoun, Pierre Feugier, Fritz Offner, Christian Récher, Aspasia Stamatoullas, F. Morschhauser, Margaret Macro, Catherine Thiéblemont, A Bosly, Bettina Fabiani, F Reyes	2003	1
19	Allogeneic bone marrow transplantation in patients with follicular lymphoma: a single center study Bone Marrow Transplantation ·Ibrahim Yakoub‐Agha, Solomiya-Volodymyra SIDORUK, C.A. Friberg, Gaëlle Guillerm, Bruno Quesnel, Pierre Fenaux, F Bauters, J P Jouet, F. Morschhauser	2002	8
20	Evaluation of Minimal Residual Disease Using Reverse-Transcription Polymerase Chain Reaction in t(8;21) Acute Myeloid Leukemia: A Multicenter Study of 51 Patients Journal of Clinical Oncology ·F. Morschhauser, JM Cayuela, Santi Martini, André Baruchel, P Rousselot, Gèrard Socié, 上谷雅孝, J.P. Jouet, Nicole Straetmans, F Sigaux, Pierre Fenaux, Claude Preudhomme	2000	60

About F. Morschhauser

F. Morschhauser is a scholar working on Pathology and Forensic Medicine, Genetics, Oncology, Hepatology and Radiation, having authored 27 papers that have together received 944 indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (22 papers), Viral-associated cancers and disorders (9 papers), Chronic Lymphocytic Leukemia Research (8 papers), Lung Cancer Treatments and Mutations (4 papers), Radiopharmaceutical Chemistry and Applications (3 papers), Monoclonal and Polyclonal Antibodies Research (3 papers), Acute Myeloid Leukemia Research (2 papers) and Medical Imaging Techniques and Applications (2 papers). The work is most often cited by research in Pathology and Forensic Medicine (693 citations), Genetics (182 citations), Oncology (449 citations), Hematology (175 citations) and Neurology (166 citations). F. Morschhauser has collaborated with scholars based in France, United States and Belgium. Frequent co-authors include Olivier Casasnovas, Pierre Feugier, Réda Bouabdallah, Pierre Fenaux, Claude Preudhomme, Daniel Olive, Luc Xerri, Jean Michel Picquenot, Pauline Brice and Daniel Birnbaum. Their work appears in journals such as Blood, Journal of Clinical Oncology, Haematologica, Hematological Oncology and European Journal of Nuclear Medicine and Molecular Imaging.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact